Multiplex pan-filovirus assay performance and reproducibility across varied geographical and resource settings.

Authors

Olivia A Smith, Sydney Merritt, Jean Paul Kompany, Nicole A Hoff, Teri Ann S Wong, Varney Kamara, Merly Tambu, Megan Halbrook, Jason Kindrachuk, Angelica L Barrall, Kamy Musene, Skylar A Martin, John Berestecky, Robert Orr, Todd Myers, Tracy MacGill, Jean-Jacques Muyembe-Tamfum, Didine Kaba, Placide Mbala-Kingebeni, Anne W Rimoin, Axel T Lehrer

Published in

PloS one. Volume 21. Issue 8. Pages e0356257. Epub Aug 20, 2026.

Abstract

Multiplex bead-based immunoassays (MIAs) are promising tools for simultaneously detecting humoral immunity to multiple targets, potentially playing a crucial role in serosurveillance and vaccine response assessments. However, evaluation of assay performance is paramount prior to widespread use. This study presents a performance evaluation of a pan-filovirus MIA through characterization of the analytical range for the EBOV glycoprotein (GP) target and assessments of assay precision and antigen discrimination. The precision of the MIA was evaluated by comparing the detection of anti-filovirus antibodies at two independent laboratory sites: the University of Hawai'i, Honolulu (UH), and the Institut National de Recherche Biomédicale (INRB) in Kinshasa, Democratic Republic of the Congo (DRC). Forty-six samples from Yambuku, DRC, including Ebola virus Disease (EVD) survivors and close contacts, were tested at both sites. Additionally, 907 samples were tested in DRC before and after vaccination with a prophylactic EVD vaccine, ERVEBO. Results demonstrated low variability between laboratories, with intra-assay and inter-laboratory coefficients of variation below predefined thresholds for all filovirus targets included in the multiplex panel. Analyte correlation between sites was high (r2 = 0.86-0.92). Longitudinal analysis detected increased EBOV GP reactivity following vaccination, while reactivity to non-vaccine filovirus antigens remained stable, consistent with minimal cross-reactivity in a vaccinated cohort. These findings suggest that this pan-filovirus MIA produces reproducible results across distinct laboratory settings and may serve as a useful tool for comparative serologic investigations, serosurveillance, and evaluation of EBOV vaccine-associated antibody responses.

PMID:
42623404
Bibliographic data and abstract were imported from PubMed on 21 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.